A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Tyler, Texas 75701, United States
Parana, Córdoba Province 5000, Argentina
Baoding Shi, Hebei 071000, China
Henan Sheng, Henan 450003, China
Hirosaki-shi, Aomori 036-8563, Japan
Sakura-Shi, Chiba 285-8741, Japan
Ube Shi, Yamaguchi 7550046, Japan
Krasnogorsk Moscow Region, 143442, Russia
Moscow, 115478, Russia
Obninsk, 249036, Russia
Omsk, 644013, Russia
Saint Petersburg, 197758, Russia
Jung-gu, Daejeon 35015, South Korea
Songnam-si, Gyeonggi-do 13620, South Korea
Jeollanam-do, 58128, South Korea
Seodaemun-Gu, 3722, South Korea
Niaosng, Kaohsiung 833, Taiwan